Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.53 |
| ▸ | TUBB | P07437 | 4/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996729 | 1.00 | KDM1A (0.72) | KDM1AMAOAMAOBNR3C1TUBB4A | |
| SCHEMBL6996727 | 1.00 | KDM1A (0.72) | KDM1AMAOAMAOBNR3C1TUBB4A | |
| SCHEMBL7868679 | 0.85 | KDM1A (0.63) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7094484 | 0.85 | KDM1A (0.63) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7094483 | 0.85 | KDM1A (0.63) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7092495 | 0.85 | KDM1A (0.68) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7002848 | 0.85 | KDM1A (0.68) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7002844 | 0.85 | KDM1A (0.68) | KDM1AMAOAMAOBTUBB4ATUBB | |
| SCHEMBL7367066 | 0.84 | PDE4B (0.60) | KDM1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7367064 | 0.84 | PDE4B (0.60) | KDM1APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| CN-103857393-B | Cyclopropylamine is as LSD1 inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| CN-105646439-A | Synergist for antifungal drugs, and preparation and application thereof | 中国人民解放军第二军医大学 | 2016-06-08 | — | — | CN | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| CN-103857393-A | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE LLC | 2014-06-11 | — | — | CN | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | KDM1A 2/4885MAOA 184/4885MAOB 200/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885MAOA 184/4885MAOB 200/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOA 39/4885MAOB 34/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOA 39/4885MAOB 34/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885MAOA 184/4885MAOB 200/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | KDM1A 14/4885MAOA 1/4885MAOB 2/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885MAOA 184/4885MAOB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.